J. Altenburg (Amsterdam (NH), Netherlands), R. Amaro Rodriguez (Premia de Dalt (Barcelona), Spain)
Tociluzimab administation and monitoring in Covid-19 N. Keidan (Newcastle, United Kingdom), A. Aujayeb (Newcastle, United Kingdom), A. Aujayeb (Newcastle, United Kingdom)
| |
Risk factors and mortality rate in hospitalized patients with COVID-19: Data from a respiratory medicine department in a reference Hospital for COVID-19 L. Kolilekas (Athens, Greece), A. Photiades (Athens, Greece), A. Levounets (Athens, Greece), K. Loverdos (Athens, Greece), L. Vlassi (Athens, Greece), P. Ntontsi (Athens, Greece), T. Agapitou (Athens, Greece), C. Kontogianni (Athens, Greece), R. Chatzipetrou (Athens, Greece), S. Giannakaki (Athens, Greece), Z. Sardelis (Athens, Greece), T. Grigoratou (Athens, Greece), E. Ekonomidou (Athens, Greece), K. Samitas (Athens, Greece), E. Zervas (Athens, Greece), M. Gaga (Athens, Greece)
| |
Mortality prediction using a modified R2CHA2DS2-VASc score among hospitalized COVID-19 patients O. Wand (Ashkelon, Israel), D. Levy (Kfar Saba, Israel), G. Topaz (Kfar Saba, Israel), S. Benchetrit (Kfar Saba, Israel), K. Cohen-Hagai (Kfar Saba, Israel)
| |
Multiple-flows exhaled nitric oxide for the detection and severity assessment of post-COVID19 lung sequelae P. Cameli (Siena (SI), Italy), E. Bargagli (Siena (SI), Italy), L. Bergantini (Siena (SI), Italy), M. D'Alessandro (Siena (SI), Italy), B. Giugno (Siena (SI), Italy), F. Gentili (Siena (SI), Italy), P. Sestini (Siena (SI), Italy)
| |
Post Coronavirus Disease 2019 (COVID-19) pulmonary fibrosis: a 12 months follow-up study M. Daverio (Padova, Italy), E. Cocconcelli (Padova, Italy), N. Bernardinello (Padova, Italy), S. Petrarulo (Padova, Italy), M. Bovo (Padova, Italy), C. Dartora (Padova, Italy), E. De Zorzi (Padova, Italy), S. Tonin (Padova, Italy), A. Cattelan (Padova, Italy), C. Giraudo (Padova, Italy), M. Saetta (Padova, Italy), P. Spagnolo (Padova, Italy), E. Balestro (Padova, Italy)
| |
COVID-19 Pneumonia Virtual Follow-up Service in Greater Glasgow and Clyde: Effectiveness and Outcomes. E. McGarry (Glasgow, United Kingdom), K. Scott (Glasgow, United Kingdom), K. Levin (Glasgow, United Kingdom), F. Refin (Glasgow, United Kingdom), A. Wright (Glasgow, United Kingdom), G. Chalmers (Glasgow, United Kingdom), D. Anderson (Glasgow, United Kingdom), B. Choo-Kang (Glasgow, United Kingdom), H. Bayes (Glasgow, United Kingdom)
| |
Lingering COVID-19 symptoms in non-hospitalized (NH) patients: Results from a Tunisian prospective cohort A. Touil (Ariana, Tunisia), E. Nemsi (Ariana, Tunisia), S. Maazaoui (Ariana, Tunisia), T. Znegui (Ariana, Tunisia), M. Chaabane (Ariana, Tunisia), S. Maddeh (Ariana, Tunisia), S. Habibech (Ariana, Tunisia), H. Racil (Ariana, Tunisia), N. Chaouch (Ariana, Tunisia)
| |
Critical patients with COVID-19: are there any clinical peculiarities? V. Rudakova (Dnipro, Ukraine), K. Gashynova (Dnipro, Ukraine), Y. Skubchenko (Dnipro, Ukraine), V. Mykhailov (Dnipro, Ukraine)
| |
CRP, ferritin, IL-6 and D-dimer: how significant they are in prediction of disease severity in COVID-19 - A retrospective study B. Božanic (Niš, Republic of Serbia), M. Topalovic (Niš, Republic of Serbia), T. Pejcic (Niš, Republic of Serbia), A. Ignjatovic (Niš, Republic of Serbia), D. Nastasijevic Borovac (Niš, Republic of Serbia), V. Pejcic (Niš, Republic of Serbia), A. Srbulovic Božanic (Leskovac, Republic of Serbia), M. Vrbic (Niš, Republic of Serbia), M. Bjelakovic (Niš, Republic of Serbia), M. Marinkovic (Niš, Republic of Serbia), M. Radovic (Niš, Republic of Serbia), M. Rancic (Niš, Republic of Serbia), I. Stankovic (Niš, Republic of Serbia), L. Ristic (Niš, Republic of Serbia)
| |
Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of the angiotensin II type 2 receptor agonist C21 on lung pathology in subjects previously hospitalised with COVID-19 R. Batta (Stockholm, Sweden), G. Tornling (Stockholm, Sweden), T. Bengtsson (Stockholm, Sweden), A. Devaraj (London, United Kingdom), R. Kashiva (Pune, India), A. Rajkondawar (Nagpur, India), K. Parmar (Ahmedabad, India), N. Bhalani (Vododara, India), A. Bohra (Milton Keynes, United Kingdom), A. Cohrt (Stockholm, Sweden), C. Ganslandt (Stockholm, Sweden)
| |
CLINICAL PHENOTYPES OF COVID-19 PNEUMONIA:different phases of viral process or really different states? Y. Huba (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine)
| |
Developing a Long-COVID follow-up protocol in a Portuguese tertiary hospital G. Canelas (Porto, Portugal), M. Gomes (Porto, Portugal), C. Nunes Silva (Porto, Portugal), A. Sarmento (Porto, Portugal), M. Tavares (Porto, Portugal)
| |
Interleukin-6 in SARS-CoV2 risk stratification F. Pereira da Silva (Guarda, Portugal), F. Luís (Guarda, Portugal), F. Jesus (Guarda, Portugal), É. Almeida (Guarda, Portugal), S. Braga (Guarda, Portugal), J. Ribeiro (Guarda, Portugal), R. Natal (Guarda, Portugal), J. Costa (Guarda, Portugal), M. Tavares (Guarda, Portugal), L. Ferreira (Guarda, Portugal)
| |
Pulmonary function evaluation after hospital discharge of patients with severe COVID-19 C. Palomeque (Tuxtla Gutierrez Chiapas, Mexico), J. Pola (Tuxtla Gutierrez Chiapas, Mexico), F. Guillén Ortega (Tuxtla Gutierrez Chiapas, Mexico)
| |
Automated cough detection in COVID-19 and non-COVID-19 pneumonia using machine learning-based technology F. Rassouli (St. Gallen, Switzerland), M. Boesch (St. Gallen, Switzerland), F. Baty (St. Gallen, Switzerland), F. Barata (Zurich, Switzerland), D. Cleres (Zurich, Switzerland), P. Tinschert (Zurich, Switzerland), I. Shih (Zurich, Switzerland), E. Fleisch (Zurich, Switzerland), M. Brutsche (St. Gallen, Switzerland)
| |
The charateristics of patients with pulmonary post covid fibrosis I. Kharrat (Kairouan, Tunisia), A. Kacem (Kairouan, Tunisia), H. Hannechi (Kairouan, Tunisia), R. Benjazia (Kairouan, Tunisia), H. Zorgati (Kairouan, Tunisia), S. Mefteh (Kairouan, Tunisia), D. Benbraiek (Kairouan, Tunisia), J. Ayachi (Kairouan, Tunisia), A. Maatalla (Kairouan, Tunisia), L. Merzougui (Kairouan, Tunisia)
| |
Association between serum IgG levels and time to first antibiotic prescription in COPD patients A. Vanoverschelde (Ghent, Belgium), S. Khan (Rotterdam, Netherlands), V. Dalm (Rotterdam, Netherlands), L. Chaker (Rotterdam, Netherlands), G. Brusselle (Ghent, Belgium), B. Stricker (Rotterdam, Netherlands), L. Lahousse (Ghent, Belgium)
| |
Clinical, radiological, and respiratory functional assessment three months after SARS-CoV-2 hypoxemic pneumonia S. Debiche (La Marsa, Tunisia), H. Snène (La Marsa, Tunisia), B. Hana (La Marsa, Tunisia), K. Line (La Marsa, Tunisia), S. Daoud (La Marsa, Tunisia), S. Ouali (La Marsa, Tunisia), J. Daghfous (La Marsa, Tunisia), N. Mehiri (La Marsa, Tunisia), N. Ben Salah (La Marsa, Tunisia), B. Louzir (La Marsa, Tunisia)
| |
Long COVID risk factors in a Portuguese cohort M. Ferreira Araújo (Matosinhos, Portugal), S. Dias ( Matosinhos, Portugal), J. Lourenço (Matosinhos, Portugal), A. Fernandes (Matosinhos, Portugal), B. Cabrita (Matosinhos, Portugal), J. Amado (Matosinhos, Portugal), A. Vaz (Matosinhos, Portugal), I. Neves (Matosinhos, Portugal), P. Simão (Matosinhos, Portugal), B. Seabra (Matosinhos, Portugal)
| |
Microbiological profile of post covid patients admitted in tertiary care center with pulmonary infections. D. Muthreja (Nagpur (Maharashtra), India)
| |